$KRTL Biotech Inc. Advances API Supply Chain Strategy with $240,000 Initial Purchase Order
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=482627
KRTL Holding Group Inc. (OTC: KRTL) today announced that its wholly owned subsidiary, KRTL Biotech Inc., has secured an initial purchase order valued at $240,000 for Thiamine Mononitrate (Vitamin B1) and Riboflavin (Vitamin B2) through the efforts of its recently expanded sales leadership team. This order represents a strategic advancement in KRTL Biotech's expansion into the active pharmaceutical ingredient (API) sector—an industry fundamental to healthcare, wellness, and global pharmaceutical production.
The initial purchase order is currently advancing through internal processing stages, including standard procurement, quality control, and documentation review. While the Company is not in a position to confirm completion until all fulfillment steps are finalized, this milestone reflects a significant movement within KRTL Biotech’s expanding commercial operations. The Company remains committed to proceeding in full compliance with applicable laws and regulatory frameworks, while maintaining internal standards for transparency, quality assurance, and professional conduct throughout the transaction lifecycle.
This order serves as a meaningful validation of KRTL Biotech’s commercial positioning and supply readiness, with emphasis on sourcing high-purity, pharmaceutical-grade vitamins. KRTL Biotech continues to strengthen its access to secure supply chain channels, capable of supporting both domestic and international client demands. These developments enhance KRTL Biotech’s capabilities in traceability, regulatory documentation, and ingredient integrity, key metrics within the pharmaceutical and nutraceutical sectors.
"Obtaining this purchase order marks a significant step forward for KRTL Biotech," said Rick Haxton, Global Sales Director of KRTL Biotech. "It reflects the strength of our sales and sourcing model, our focus on quality, and the confidence that clients place in our execution. This milestone represents the beginning of a broader market engagement strategy aimed at scaling responsibly and compliantly."
The purchase order is expected to contribute to KRTL Biotech’s 2025 growth initiatives and further establish its profile as a reliable and compliant supplier in the global API and nutraceutical supply ecosystem
https://www.otcmarkets.com/stock/KRTL/news/KR...?id=482627
KRTL Holding Group Inc. (OTC: KRTL) today announced that its wholly owned subsidiary, KRTL Biotech Inc., has secured an initial purchase order valued at $240,000 for Thiamine Mononitrate (Vitamin B1) and Riboflavin (Vitamin B2) through the efforts of its recently expanded sales leadership team. This order represents a strategic advancement in KRTL Biotech's expansion into the active pharmaceutical ingredient (API) sector—an industry fundamental to healthcare, wellness, and global pharmaceutical production.
The initial purchase order is currently advancing through internal processing stages, including standard procurement, quality control, and documentation review. While the Company is not in a position to confirm completion until all fulfillment steps are finalized, this milestone reflects a significant movement within KRTL Biotech’s expanding commercial operations. The Company remains committed to proceeding in full compliance with applicable laws and regulatory frameworks, while maintaining internal standards for transparency, quality assurance, and professional conduct throughout the transaction lifecycle.
This order serves as a meaningful validation of KRTL Biotech’s commercial positioning and supply readiness, with emphasis on sourcing high-purity, pharmaceutical-grade vitamins. KRTL Biotech continues to strengthen its access to secure supply chain channels, capable of supporting both domestic and international client demands. These developments enhance KRTL Biotech’s capabilities in traceability, regulatory documentation, and ingredient integrity, key metrics within the pharmaceutical and nutraceutical sectors.
"Obtaining this purchase order marks a significant step forward for KRTL Biotech," said Rick Haxton, Global Sales Director of KRTL Biotech. "It reflects the strength of our sales and sourcing model, our focus on quality, and the confidence that clients place in our execution. This milestone represents the beginning of a broader market engagement strategy aimed at scaling responsibly and compliantly."
The purchase order is expected to contribute to KRTL Biotech’s 2025 growth initiatives and further establish its profile as a reliable and compliant supplier in the global API and nutraceutical supply ecosystem
